Drug Trial Radar · NCT05941806
Prophylactic Use of Tamsulosin in the Prevention of Post-operative Urinary Retention in Men After Rectum Resection
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Nov 10, 2023
Primary completion
Jul 30, 2027
Study completion Jul 30, 2028
Sponsor
- Lead sponsor
- CHU de Quebec-Universite LavalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fédération des médecins résidents du Québec
- First posted
- Jul 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will be a phase III double-blind randomized clinical trial. Participants will be recruited from the Department of General Surgery of the CHU de Québec - Saint-François-d'Assise and Hôtel-Dieu de Québec. The primary outcomes are the incidence of postoperative urinary retention in men undergoing rectal resection and the efficacy of prophylactic tamsulosin to prevent this type of complication.The secondary outcomes are the length of stay between experimental and placebo groups, the number of urinary catheterizations, the number of urine catheter reinsertions and total duration of urinary catheter being in-situ.
Conditions
- Urinary Retention
- Colorectal Surgery
- Rectal Resection
- Post-operative Urinary Retention
- Tamsulosin
Interventions
pr Sandoz TamsulosinDrug
Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.
GlucoseDrug
Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postoperative urinary retentionTime frame: During the length of hospital stay: up to two weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Saint-François d'Assise
Québec, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.